Literature DB >> 10426180

Costs arising from otitis media.

M Niemelä1, M Uhari, M Möttönen, T Pokka.   

Abstract

Otitis media (OM) is one of the most common diseases of childhood, and causes both direct and indirect costs to families and to society. This study calculated the costs arising from OM among 736 day care children whose infections were prospectively monitored for up to 15 mo in 10 day care centres in the city of Oulu. The children in the survey had 1.5 attacks of acute OM per person year, made 2.1 visits to a physician (cost $US55 visit(-1)) and received 1.5 courses of antimicrobials (cost $24 course(-1)). Their parents were absent from work for 1.9 d per person year (cost $85 d(-1)). Either adenoidectomy ($890 operation(-1)) or tympanostomy ($740) was performed on 6% of the children and the overall costs of surgery were $80 per person year at risk. In total, each single attack of acute OM cost $228. The average annual costs per child younger than 2 y were $1040, those for children aged 2-3 y $283 and those for children older than 3 y $141. The cumulative costs from age 6 mo to 7 y were $2549 child(-1). When the attributable risk of OM at a day care centre is taken into account, in Finland, a country with about 5 million inhabitants, OM gives rise to total annual costs of $US138 million. OM leads to considerable expenses and even expensive preventive measures would be cost-effective.

Entities:  

Mesh:

Year:  1999        PMID: 10426180     DOI: 10.1080/08035259950169585

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  10 in total

1.  Treatment cost effectiveness in acute otitis media: A watch-and-wait approach versus amoxicillin.

Authors:  Isabelle Gaboury; Kathryn Coyle; Douglas Coyle; Nicole Le Saux
Journal:  Paediatr Child Health       Date:  2010-09       Impact factor: 2.253

2.  Effect of pneumococcal vaccination on otitis media with effusion in children older than 1 year.

Authors:  Thuy-My Le; Maroeska M Rovers; Reinier H Veenhoven; Elisabeth A M Sanders; Anne G M Schilder
Journal:  Eur J Pediatr       Date:  2006-12-30       Impact factor: 3.183

Review 3.  Importance of respiratory viruses in acute otitis media.

Authors:  Terho Heikkinen; Tasnee Chonmaitree
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

4.  The burden of acute otitis media on the patient and the family.

Authors:  David Greenberg; Natasha Bilenko; Zvika Liss; Tomer Shagan; Orly Zamir; Ron Dagan
Journal:  Eur J Pediatr       Date:  2003-06-19       Impact factor: 3.183

5.  Current and Future Prospects for a Vaccine for Nontypeable Haemophilus influenzae.

Authors:  Timothy F Murphy
Journal:  Curr Infect Dis Rep       Date:  2009-05       Impact factor: 3.725

6.  Societal costs and burden of otitis media in Portugal.

Authors:  Anouk Speets; Judith Wolleswinkel; Cristina Cardoso
Journal:  J Multidiscip Healthc       Date:  2011-04-04

7.  Economic cost of dengue in Puerto Rico.

Authors:  Yara A Halasa; Donald S Shepard; Wu Zeng
Journal:  Am J Trop Med Hyg       Date:  2012-05       Impact factor: 2.345

8.  Intranasal fluticasone propionate does not prevent acute otitis media during viral upper respiratory infection in children.

Authors:  A Ruohola; T Heikkinen; M Waris; T Puhakka; O Ruuskanen
Journal:  J Allergy Clin Immunol       Date:  2000-09       Impact factor: 10.793

Review 9.  Grommets (ventilation tubes) for recurrent acute otitis media in children.

Authors:  Roderick P Venekamp; Paul Mick; Anne Gm Schilder; Desmond A Nunez
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09

10.  Xylitol for the prevention of acute otitis media episodes in children aged 2-4 years: protocol for a pragmatic randomised controlled trial.

Authors:  Nav Persaud; Andreas Laupacis; Amir Azarpazhooh; Catherine Birken; Jeffrey S Hoch; Wanrudee Isaranuwatchai; Jonathan L Maguire; Muhammad M Mamdani; Kevin Thorpe; Christopher Allen; Dalah Mason; Christine Kowal; Farnaz Bazeghi; Patricia Parkin
Journal:  BMJ Open       Date:  2018-08-05       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.